---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-275910"
form_type: "8-K"
ticker: "IMA"
cik: "0001835579"
company_name: "ImageneBio, Inc."
filed_at: "2025-11-12T23:59:59+00:00"
generated_at: "2026-05-16T21:30:58.171367+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# ImageneBio reports Q3 net loss of $24.8M; advances Phase 2b AD trial with protocol amendment

## Summary
- Cash, equivalents, and marketable securities $142.6M as of Sep 30, 2025; net loss $24.8M for Q3 2025 vs $3.2M in Q3 2024; R&D $15.6M, G&A $11.0M.
- Phase 2b ADAPTIVE trial protocol amendment to expand dosing regimens; topline data expected in 2027; enrollment ongoing.
- New alopecia areata data (Phase 1b/2a) and atopic dermatitis data to be presented at ISDS Nov 12-15, 2025.
- Completed reverse merger with Ikena Oncology and $75M private placement; new CEO Kristin Yarema, CSO Kurinji Pandiyan, CTO Renuka Sivendran, and independent director Joe Slattery.

## SEC filing metadata
- accession: 0001193125-25-275910
- form_type: 8-K
- ticker: IMA
- cik: 0001835579
- company_name: ImageneBio, Inc.
- filed_at: 2025-11-12T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1835579/000119312525275910/0001193125-25-275910-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1835579/000119312525275910/d61077d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-275910
- JSON: https://secwatch.observer/filing/0001193125-25-275910.json
- Plain text: https://secwatch.observer/filing/0001193125-25-275910.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.